• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

成功构建一种高效的靶向双唾液酸神经节苷脂(GD2)阳性肿瘤的单链可变片段(scFv)双特异性抗体。

Successful engineering of a highly potent single-chain variable-fragment (scFv) bispecific antibody to target disialoganglioside (GD2) positive tumors.

作者信息

Cheng Ming, Santich Brian H, Xu Hong, Ahmed Mahiuddin, Huse Morgan, Cheung Nai-Kong V

机构信息

Department of Pediatrics, Memorial Sloan Kettering Cancer Center , New York, NY, USA.

Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

出版信息

Oncoimmunology. 2016 May 5;5(6):e1168557. doi: 10.1080/2162402X.2016.1168557. eCollection 2016 Jun.

DOI:10.1080/2162402X.2016.1168557
PMID:27471647
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4938304/
Abstract

Engineering potent bispecific antibodies from single-chain variable fragments (scFv) remains difficult due to the inherent instability and insufficient binding of scFv's compared to their parental immunoglobulin format. Previously, we described a scFv-based bispecific antibody (scBA) against disialoganglioside (GD2) based on the anti-GD2 murine 5F11-scFv and the anti-CD3 huOKT3-scFv (5F11-scBA). In this study, we substituted the 5F11-scFv with the higher affinity (13-fold) hu3F8-scFv to form hu3F8-scBA. With this modification, hu3F8-scBA redirected T cells to kill GD2(+) cancer cell lines with up to 5,000-fold higher potency (femtomolar EC50) compared with 5F11-scBA (picomolar EC50) in cytotoxicity assays, even against target cells with low GD2 densities. Furthermore, hu3F8-scBA induced stronger T-cell activation than 5F11-scBA, as measured by Ca(2+) flux and cytokine release. Additionally, in vivo, hu3F8-scBA suppressed tumor growth and prolonged mice survival much more effectively than 5F11-scBA, in both neuroblastoma and melanoma xenograft models. We conclude that the functional properties of scBA's can be increased substantially by relatively modest increases in antigen affinity.

摘要

相较于其亲本免疫球蛋白形式,单链可变片段(scFv)固有的不稳定性和结合力不足使得工程化高效双特异性抗体仍然具有挑战性。此前,我们报道了一种基于抗GD2鼠源5F11-scFv和抗CD3人源OKT3-scFv的抗双唾液酸神经节苷脂(GD2)双特异性抗体(scBA)(5F11-scBA)。在本研究中,我们用亲和力更高(高13倍)的人源3F8-scFv替换5F11-scFv以形成人源3F8-scBA。通过这种修饰,在细胞毒性试验中,人源3F8-scBA重定向T细胞杀伤GD2(+)癌细胞系的效力比5F11-scBA(皮摩尔EC50)高5000倍(飞摩尔EC50),甚至对低GD2密度的靶细胞也有效。此外,通过Ca(2+)通量和细胞因子释放检测发现,人源3F8-scBA比5F11-scBA诱导更强的T细胞活化。另外,在体内,在神经母细胞瘤和黑色素瘤异种移植模型中,人源3F8-scBA比5F11-scBA更有效地抑制肿瘤生长并延长小鼠存活时间。我们得出结论,通过相对适度地提高抗原亲和力可显著增强scBA的功能特性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2847/4938304/4ea31d7e6359/koni-05-06-1168557-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2847/4938304/1eb7063413f9/koni-05-06-1168557-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2847/4938304/719de4736167/koni-05-06-1168557-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2847/4938304/d07893fd9eab/koni-05-06-1168557-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2847/4938304/e120ede7a4db/koni-05-06-1168557-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2847/4938304/4ea31d7e6359/koni-05-06-1168557-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2847/4938304/1eb7063413f9/koni-05-06-1168557-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2847/4938304/719de4736167/koni-05-06-1168557-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2847/4938304/d07893fd9eab/koni-05-06-1168557-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2847/4938304/e120ede7a4db/koni-05-06-1168557-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2847/4938304/4ea31d7e6359/koni-05-06-1168557-g005.jpg

相似文献

1
Successful engineering of a highly potent single-chain variable-fragment (scFv) bispecific antibody to target disialoganglioside (GD2) positive tumors.成功构建一种高效的靶向双唾液酸神经节苷脂(GD2)阳性肿瘤的单链可变片段(scFv)双特异性抗体。
Oncoimmunology. 2016 May 5;5(6):e1168557. doi: 10.1080/2162402X.2016.1168557. eCollection 2016 Jun.
2
Retargeting T cells to GD2 pentasaccharide on human tumors using Bispecific humanized antibody.使用双特异性人源化抗体将 T 细胞重定向到人肿瘤上的 GD2 五糖。
Cancer Immunol Res. 2015 Mar;3(3):266-77. doi: 10.1158/2326-6066.CIR-14-0230-T. Epub 2014 Dec 26.
3
Potent antitumor effect of T cells armed with anti-GD2 bispecific antibody.携抗 GD2 双特异性抗体的 T 细胞具有强大的抗肿瘤作用。
Pediatr Blood Cancer. 2021 Jul;68(7):e28971. doi: 10.1002/pbc.28971. Epub 2021 Apr 12.
4
Single-chain Fv-streptavidin substantially improved therapeutic index in multistep targeting directed at disialoganglioside GD2.单链Fv-链霉亲和素在针对双唾液酸神经节苷脂GD2的多步靶向治疗中显著提高了治疗指数。
J Nucl Med. 2004 May;45(5):867-77.
5
Structural design of disialoganglioside GD2 and CD3-bispecific antibodies to redirect T cells for tumor therapy.双唾液酸神经节苷脂GD2与CD3双特异性抗体的结构设计,用于重定向T细胞进行肿瘤治疗。
Int J Cancer. 2015 Jan 15;136(2):476-86. doi: 10.1002/ijc.29007. Epub 2014 Jun 19.
6
Generation and characterization of a mouse single-chain antibody fragment specific for disialoganglioside (GD2).一种针对双唾液酸神经节苷脂(GD2)的小鼠单链抗体片段的产生与特性分析
Hybridoma. 1997 Aug;16(4):335-46. doi: 10.1089/hyb.1997.16.335.
7
Alteration of Electrostatic Surface Potential Enhances Affinity and Tumor Killing Properties of Anti-ganglioside GD2 Monoclonal Antibody hu3F8.静电表面电位的改变增强了抗神经节苷脂GD2单克隆抗体hu3F8的亲和力和肿瘤杀伤特性。
J Biol Chem. 2015 May 22;290(21):13017-27. doi: 10.1074/jbc.M115.650903. Epub 2015 Apr 7.
8
Chimeric single-chain variable fragment-human immunoglobulin G crystallizable fragment antibody against GD2 for neuroblastoma targeted immunotherapy.用于神经母细胞瘤靶向免疫治疗的抗GD2嵌合单链可变片段-人免疫球蛋白G可结晶片段抗体。
Explor Target Antitumor Ther. 2023;4(6):1145-1156. doi: 10.37349/etat.2023.00188. Epub 2023 Dec 6.
9
Human derived dimerization tag enhances tumor killing potency of a T-cell engaging bispecific antibody.人源二聚化标签增强了T细胞衔接双特异性抗体的肿瘤杀伤效力。
Oncoimmunology. 2015 Apr 27;4(4):e989776. doi: 10.4161/2162402X.2014.989776. eCollection 2015 Apr.
10
Bispecific antibody does not induce T-cell death mediated by chimeric antigen receptor against disialoganglioside GD2.双特异性抗体不会诱导由嵌合抗原受体介导的针对双唾液酸神经节苷脂GD2的T细胞死亡。
Oncoimmunology. 2017 Apr 28;6(6):e1320625. doi: 10.1080/2162402X.2017.1320625. eCollection 2017.

引用本文的文献

1
Dual targeting of tumoral cells and immune microenvironment by blocking the IL-33/IL1RL1 pathway.通过阻断IL-33/IL1RL1通路对肿瘤细胞和免疫微环境进行双重靶向作用。
Nat Commun. 2025 Jul 14;16(1):6369. doi: 10.1038/s41467-025-61567-7.
2
Biology of GD2 ganglioside: implications for cancer immunotherapy.GD2神经节苷脂生物学:对癌症免疫治疗的启示
Front Pharmacol. 2023 Aug 21;14:1249929. doi: 10.3389/fphar.2023.1249929. eCollection 2023.
3
Manufacturability and functionality assessment of different formats of T-cell engaging bispecific antibodies.

本文引用的文献

1
Human derived dimerization tag enhances tumor killing potency of a T-cell engaging bispecific antibody.人源二聚化标签增强了T细胞衔接双特异性抗体的肿瘤杀伤效力。
Oncoimmunology. 2015 Apr 27;4(4):e989776. doi: 10.4161/2162402X.2014.989776. eCollection 2015 Apr.
2
Alteration of Electrostatic Surface Potential Enhances Affinity and Tumor Killing Properties of Anti-ganglioside GD2 Monoclonal Antibody hu3F8.静电表面电位的改变增强了抗神经节苷脂GD2单克隆抗体hu3F8的亲和力和肿瘤杀伤特性。
J Biol Chem. 2015 May 22;290(21):13017-27. doi: 10.1074/jbc.M115.650903. Epub 2015 Apr 7.
3
Alternative molecular formats and therapeutic applications for bispecific antibodies.
不同格式的 T 细胞结合双特异性抗体的可制造性和功能评估。
MAbs. 2023 Jan-Dec;15(1):2231129. doi: 10.1080/19420862.2023.2231129.
4
Smaller size packs a stronger punch - Recent advances in small antibody fragments targeting tumour-associated carbohydrate antigens.小体积,大能量——针对肿瘤相关碳水化合物抗原的小分子抗体片段的最新进展。
Theranostics. 2023 May 15;13(9):3041-3063. doi: 10.7150/thno.80901. eCollection 2023.
5
Integrin-directed antibody-based immunotherapy: focus on VLA-4.整合素导向的基于抗体的免疫疗法:聚焦于VLA-4
Immunother Adv. 2021 Feb 9;1(1):ltab002. doi: 10.1093/immadv/ltab002. eCollection 2021 Jan.
6
Bispecific antibodies for the treatment of neuroblastoma.双特异性抗体治疗神经母细胞瘤。
Pharmacol Ther. 2022 Sep;237:108241. doi: 10.1016/j.pharmthera.2022.108241. Epub 2022 Jul 10.
7
Targeting Tumor Glycans for Cancer Therapy: Successes, Limitations, and Perspectives.靶向肿瘤聚糖用于癌症治疗:成功、局限与展望
Cancers (Basel). 2022 Jan 27;14(3):645. doi: 10.3390/cancers14030645.
8
Novel potent anti-STEAP1 bispecific antibody to redirect T cells for cancer immunotherapy.新型强效抗 STEAP1 双特异性抗体,用于重定向 T 细胞进行癌症免疫治疗。
J Immunother Cancer. 2021 Sep;9(9). doi: 10.1136/jitc-2021-003114.
9
GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma.GD2 导向的双特异性三功能抗体在侵袭性转移性神经母细胞瘤的小鼠模型中优于 dinutuximab beta。
J Immunother Cancer. 2021 Jul;9(7). doi: 10.1136/jitc-2021-002923.
10
The Role of Sphingolipids in Cancer Immunotherapy.鞘脂在癌症免疫治疗中的作用。
Int J Mol Sci. 2021 Jun 17;22(12):6492. doi: 10.3390/ijms22126492.
双特异性抗体的替代分子形式及治疗应用
Mol Immunol. 2015 Oct;67(2 Pt A):95-106. doi: 10.1016/j.molimm.2015.01.003. Epub 2015 Jan 27.
4
Disialoganglioside GD2 as a therapeutic target for human diseases.双唾液酸神经节苷脂GD2作为人类疾病的治疗靶点。
Expert Opin Ther Targets. 2015 Mar;19(3):349-62. doi: 10.1517/14728222.2014.986459. Epub 2015 Jan 20.
5
Retargeting T cells to GD2 pentasaccharide on human tumors using Bispecific humanized antibody.使用双特异性人源化抗体将 T 细胞重定向到人肿瘤上的 GD2 五糖。
Cancer Immunol Res. 2015 Mar;3(3):266-77. doi: 10.1158/2326-6066.CIR-14-0230-T. Epub 2014 Dec 26.
6
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.Blinatumomab 治疗成人复发/难治性 B 前体急性淋巴细胞白血病患者的安全性和疗效:一项多中心、单臂、2 期研究。
Lancet Oncol. 2015 Jan;16(1):57-66. doi: 10.1016/S1470-2045(14)71170-2. Epub 2014 Dec 16.
7
GD2-targeted immunotherapy and radioimmunotherapy.靶向GD2的免疫疗法和放射免疫疗法。
Semin Oncol. 2014 Oct;41(5):589-612. doi: 10.1053/j.seminoncol.2014.07.003. Epub 2014 Jul 21.
8
Engineering disulfide bonds within an antibody.在抗体内部构建二硫键。
Biochim Biophys Acta. 2014 Nov;1844(11):2016-2023. doi: 10.1016/j.bbapap.2014.07.005. Epub 2014 Jul 17.
9
Structural design of disialoganglioside GD2 and CD3-bispecific antibodies to redirect T cells for tumor therapy.双唾液酸神经节苷脂GD2与CD3双特异性抗体的结构设计,用于重定向T细胞进行肿瘤治疗。
Int J Cancer. 2015 Jan 15;136(2):476-86. doi: 10.1002/ijc.29007. Epub 2014 Jun 19.
10
Affinity improvement of a therapeutic antibody to methamphetamine and amphetamine through structure-based antibody engineering.通过基于结构的抗体工程提高治疗性抗体对甲基苯丙胺和苯丙胺的亲和力。
Sci Rep. 2014 Jan 14;4:3673. doi: 10.1038/srep03673.